ArticleInfectious medicine2022
Oral and ocular transmission of severe fever with thrombocytopenia syndrome virus.
Article in Infectious medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Interplay between SFTSV and host innate immunity: Viral evasion mechanisms, pathogenesis, and therapeutic perspectives.iScience · 2026Review
- Differential immune responses to SFTSV Gn and Gc mRNA vaccines in mice and dogs.Microbiology spectrum · 2026Article
- Development and Validation of a Novel Predictive Model and Simplified Clinical Indicator for Mortality in Severe Fever with Thrombocytopenia Syndrome Patients.Infection and drug resistance · 2026Article
- Establishment of a rapid detection method for severe fever with thrombocytopenia syndrome virus based on reverse transcription-recombinase polymerase amplification with lateral flow nucleic acid chromatography assay technology.Frontiers in microbiology · 2026Article
- SFTSV Prevalence in Ticks and Livestock in an SFTSV-Endemic Area in Central China.Pathogens (Basel, Switzerland) · 2025Article
- SFTSV NSs degrades SAFA via autophagy to suppress SAFA-dependent antiviral response.PLoS pathogens · 2025Article
- Genome-wide CRISPR screening identifies LRP1 as an entry factor for SFTSV.Nature communications · 2025Article
- Two-transcript signature for differentiation and clinical outcomes in severe fever with thrombocytopenia syndrome (SFTS) patients: a double-blind, multicenter, validation study.Journal of clinical microbiology · 2025Article
- Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge.PLoS pathogens · 2025Article
- Review
- SFTSV nucleoprotein mediates DNA sensor cGAS degradation to suppress cGAS-dependent antiviral responses.Microbiology spectrum · 2024Article
- Risk assessment of human-to-human transmission of severe fever with thrombocytopenia syndrome virus based on 10-year clustered analysis.Frontiers in public health · 2024Article
- Changes in Cytokine Levels in Patients with Severe Fever with Thrombocytopenia Syndrome Virus.Journal of inflammation research · 2024Article
- Reactivation of Epstein-Barr virus in SFTSV infected patients.Infectious medicine · 2023Article
- SFTSV infection in rodents and their ectoparasitic chiggers.PLoS neglected tropical diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne bunyavirus that could cause a severe hemorrhagic fever termed SFTS with a high fatality rate of up to 30%. Importantly, SFTSV is frequently transmitted from person-to-person and patients' blood or excreta are considered as the risk factors for transmission of SFTSV. However, the mechanism of person-to-person transmission of SFTSV is still elusive. Methods: In this study, wild-type (WT) C57BL/6 J mice and a lethal SFTSV mouse model Results: We found that SFTSV antibody positive rates in C57BL/6 J mice were 70% (7/10) and 30% (3/10) in the oral inoculation group and ocular inoculation group, respectively on day 21 post SFTSV inoculation. The mortality rates of Conclusions: Together, our results show that SFTSV can be transmitted effectively through oral and ocular membrane, suggesting exposure to SFTS positive excreta may be a high-risk factor of nosocomial transmission of SFTSV in hospitals and/or families. Family members and healthcare workers should be protected properly during taking care of SFTS patients to prevent SFTSV nosocomial infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.